(Sharecast News) - Sareum updated investors on progress across its pipeline ahead of its annual general meeting on Tuesday, highlighting continued advances in its lead autoimmune candidate SDC-1801 and strengthening commercial positioning for its cancer assets SDC-1802 and SRA737.
Executive chairman Dr Stephen Parker said the AIM-traded company was "well-positioned to...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE